Overview
This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.
Eligibility
Inclusion Criteria:
- Clinically suspected or histologically confirmed solid or hematological malignancy
- Undergoing genetic testing of tumor
- Ability to understand written informed consent document
- Willingness to sign written informed consent document
Exclusion Criteria:
- Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee